{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:15:09Z","timestamp":1777623309819,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.eplepsyres.2021.106649","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T12:00:06Z","timestamp":1620820806000},"page":"106649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0338-6039","authenticated-orcid":false,"given":"Gregory L.","family":"Krauss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elinor","family":"Ben-Menachem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Patten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9739-6598","authenticated-orcid":false,"given":"Betsy","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Laurenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-8284","authenticated-orcid":false,"given":"Manoj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2021.106649_bib0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1528-1157.1979.tb04857.x","article-title":"Remission of seizures and relapse in patients with epilepsy","volume":"20","author":"Annegers","year":"1979","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.seizure.2011.10.009","article-title":"Physical injuries in patients with epilepsy and their associated risk factors","volume":"21","author":"Asadi-Pooya","year":"2012","journal-title":"Seizure"},{"issue":"Suppl 1","key":"10.1016\/j.eplepsyres.2021.106649_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1528-1167.2007.00994.x","article-title":"Plasticity of antiepileptic drug targets","volume":"48","author":"Beck","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1528-1157.1996.tb00507.x","article-title":"Predictors of intractable epilepsy in childhood: a case-control study","volume":"37","author":"Berg","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1528-1157.2002.32201.x","article-title":"Seizure reduction and quality of life improvements in people with epilepsy","volume":"43","author":"Birbeck","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0030","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","article-title":"Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial","volume":"11","author":"Bonnett","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0404.1999.tb07360.x","article-title":"Early predictors of intractability in childhood epilepsy: a community-based case-control study in Copparo, Italy","volume":"99","author":"Casetta","year":"1999","journal-title":"Acta Neurol Scand."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1528-1157.1992.tb02281.x","article-title":"Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy","volume":"33","author":"Collaborative Group for the Study of Epilepsy","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14581\/jer.18005","article-title":"Predictors of seizure-related injuries in an epilepsy cohort from North India","volume":"8","author":"Dabla","year":"2018","journal-title":"J. Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0050","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/14656566.2017.1392509","article-title":"AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives","volume":"18","author":"Di Bonaventura","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0055","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.12669\/pjms.334.13194","article-title":"The long-term prognosis of epilepsy patients with medically treated over a period of eight years in Turkey","volume":"33","author":"Duman","year":"2017","journal-title":"Pak. J. Med. Sci."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0060","series-title":"Fycompa\u00ae Annex I: Summary of Product Characteristics","author":"European Medicines Agency","year":"2017"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/epi.16413","article-title":"Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures","volume":"61","author":"Fogarasi","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0070","series-title":"FYCOMPA\u00ae Prescribing Information, September 2020","author":"Food and Drug Administration (FDA)","year":"2020"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0075","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0085","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0090","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0095","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0100","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1528-1167.2011.03354.x","article-title":"Do antiepileptic drugs or generalized tonic-clonic seizure frequency increase SUDEP risk? A combined analysis","volume":"53","author":"Hesdorffer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0110","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/epi.12328","article-title":"Epilepsy and risk of death and sudden unexpected death in the young: a nationwide study","volume":"54","author":"Holst","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0115","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/epi.14596","article-title":"The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"59","author":"Kalilani","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0120","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S1388-2457(99)00068-1","article-title":"EEG and clinical predictors of medically intractable childhood epilepsy","volume":"110","author":"Ko","year":"1999","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0125","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/epi.12527","article-title":"Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of Phase III studies","volume":"55","author":"Kramer","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0130","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0135","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/epi.14044","article-title":"Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307","volume":"59","author":"Krauss","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0140","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0145","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0150","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/epi.12022","article-title":"Long-term outcome of phenobarbital treatment for epilepsy in rural China: a prospective cohort study","volume":"54","author":"Kwan","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0155","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1046\/j.1528-1157.2001.0420081025.x","article-title":"Remission of seizures in a population-based adult cohort with a newly diagnosed unprovoked epileptic seizure","volume":"42","author":"Lindsten","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1212\/WNL.47.1.68","article-title":"Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group","volume":"47","author":"Mattson","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0166-2236(93)90093-2","article-title":"The TINS\/TiPS lecture. The molecular biology of mammalian glutamate receptor channels","volume":"16","author":"Seeburg","year":"1993","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0175","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.51.5.1256","article-title":"Is the underlying cause of epilepsy a major prognostic factor for recurrence?","volume":"51","author":"Semah","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0180","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1528-1157.1993.tb02114.x","article-title":"Remission of seizures and predictors of intractability in long-term follow-up","volume":"34","author":"Sillanpaa","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0185","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJM199806113382402","article-title":"Long-term prognosis of seizures with onset in childhood","volume":"338","author":"Sillanpaa","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0190","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0195","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/epi.16428","article-title":"Efficacy and safety of adjunctive perampanel 4 mg\/d for the treatment of focal seizures: a pooled post hoc analysis of four randomized, double-blind, phase III studies","volume":"61","author":"Steinhoff","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0200","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.yebeh.2005.11.007","article-title":"Pharmacological outcomes in older people with newly diagnosed epilepsy","volume":"8","author":"Stephen","year":"2006","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0205","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ane.12874","article-title":"Pharmacokinetic\/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures","volume":"137","author":"Takenaka","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0210","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/epi.12666","article-title":"Sudden unexpected death in epilepsy: assessing the public health burden","volume":"55","author":"Thurman","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106649_bib0215","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3389\/fneur.2017.00658","article-title":"Initial response to antiepileptic drugs in patients with newly diagnosed epilepsy as a predictor of long-term outcome","volume":"8","author":"Xia","year":"2017","journal-title":"Front. Neurol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121001029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121001029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:45:58Z","timestamp":1760276758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121121001029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":43,"alternative-id":["S0920121121001029"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106649","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106649"}}